 |
|
Children with sickle cell disease and silent strokes show some relief with blood transfusion therapy
December 11, 2007A group of children who have sickle cell disease and who experience silent strokes showed some relief from the silent strokes with blood transfusion therapy, researchers at Washington University School of Medicine in St. Louis have found.
The study's results will appear in a future issue of Pediatric Blood and Cancer but are available for review in its advance online publication.
In a Phase II study of 10 children with sickle cell disease who also had multiple silent strokes, or cerebral infarcts, the majority of families were committed to having their children receive blood transfusions for two years, showing that the therapy was feasible. In addition, the blood transfusion therapy helped to shrink the lesions on the brain caused by the infarcts and eliminated one lesion completely, said Allison A. King, M.D., a pediatric hematologist at St. Louis Children's Hospital and a researcher at Washington University School of Medicine. Lesions are small areas of damaged tissue thought to be due to blockage of small arteries in the brain.
Silent strokes are strokes that don't show the classic symptoms of overt strokes, such as numbness, tingling, headache or slurred speech. Blood transfusion therapy has been shown to be effective in preventing overt strokes in patients with sickle cell disease, but its effectiveness and the willingness of families to participate in long-term treatment to prevent silent strokes had not been tested.
Sickle cell disease is an inherited blood disorder affecting red blood cells that contain hemoglobin, a substance that carries oxygen from the air in the lungs to all parts of the body. In patients with this disease, red blood cells contain an abnormal type of hemoglobin that causes the normally round, flexible red blood cells to become sickle- or crescent-shaped. The sickle cells can't pass through tiny blood vessels, preventing blood from reaching the body's tissues, which can result in tissue and organ damage, pain and stroke.
Sickle cell disease affects about 70,000 people in the United States. It occurs in about 1 of every 500 African-American births and 1 of every 1,000 to 1,400 Hispanic-American births. While there is no cure for the disease, blood transfusions and bone marrow transplants have been shown to be effective treatments by replacing short-lived sickle cells with longer-lived healthy red blood cells, although bone marrow transplants have a 10 percent mortality rate because of the possibility of rejecting the bone marrow, complications such as seizures and a high risk of infection.
In the study, brain lesions in six patients shrank after two years of regular blood transfusions, and no new silent strokes occurred. One patient had a lesion disappear, however, that patient did not continue with further blood transfusions, and the lesion returned at more than three times its original size, suggesting the need for prolonged transfusions. A lesion grew larger in the seventh patient.
Many of the lesions occur in the frontal lobe of the brain, which controls the cognitive function or problem-solving area, or in the occipital lobe, which controls the visual processing center, King said. Neuroradiologists can locate the lesions using magnetic resonance imaging (MRI).
"Because these lesions are usually in the frontal lobe, it is important to do cognitive testing on these children to determine any impairment," King said. "We hope that by preventing further lesions through blood transfusions that we can preserve their ability to think and learn."
A total of 71 percent of the school-aged children in the study were receiving special education services and 57 percent had failed a grade in school. Previous School of Medicine research shows that 80 percent of students with silent strokes perform poorly in school.
King said the results of the trial were encouraging to health-care professionals treating children with sickle cell disease.
"What we found in this trial is that families and children with sickle cell disease and who experience silent strokes are willing to commit to blood transfusion therapy for this condition," King said. "If these children are left untreated, their risk for an overt stroke is very high, but if we use blood transfusion therapy, they may have a lower risk for overt stroke and no evidence of new silent infarcts on an MRI."
Results of this Phase II trial spearheaded a larger, Phase III study that is evaluating 1,800 children in the United States, Canada and Europe. That trial, called the Silent Cerebral Infarct Multi-Center Clinical Trial, is headed by Michael R. DeBaun, M.D., professor of pediatrics at the School of Medicine. Through it, researchers will further determine the effectiveness of blood transfusion therapy to prevent silent strokes in children with sickle cell disease and to prevent further cerebral injury.
Washington University School of Medicine in St. Louis
Silent strokes are strokes that don't show the classic symptoms of overt strokes, such as numbness, tingling, headache or slurred speech. Blood transfusion therapy has been shown to be effective in preventing overt strokes in patients with sickle cell disease, but its effectiveness and the willingness of families to participate in long-term treatment to prevent silent strokes had not been tested.
Sickle cell disease is an inherited blood disorder affecting red blood cells that contain hemoglobin, a substance that carries oxygen from the air in the lungs to all parts of the body. In patients with this disease, red blood cells contain an abnormal type of hemoglobin that causes the normally round, flexible red blood cells to become sickle- or crescent-shaped. The sickle cells can't pass through tiny blood vessels, preventing blood from reaching the body's tissues, which can result in tissue and organ damage, pain and stroke.
Sickle cell disease affects about 70,000 people in the United States. It occurs in about 1 of every 500 African-American births and 1 of every 1,000 to 1,400 Hispanic-American births. While there is no cure for the disease, blood transfusions and bone marrow transplants have been shown to be effective treatments by replacing short-lived sickle cells with longer-lived healthy red blood cells, although bone marrow transplants have a 10 percent mortality rate because of the possibility of rejecting the bone marrow, complications such as seizures and a high risk of infection.
In the study, brain lesions in six patients shrank after two years of regular blood transfusions, and no new silent strokes occurred. One patient had a lesion disappear, however, that patient did not continue with further blood transfusions, and the lesion returned at more than three times its original size, suggesting the need for prolonged transfusions. A lesion grew larger in the seventh patient.
Many of the lesions occur in the frontal lobe of the brain, which controls the cognitive function or problem-solving area, or in the occipital lobe, which controls the visual processing center, King said. Neuroradiologists can locate the lesions using magnetic resonance imaging (MRI).
"Because these lesions are usually in the frontal lobe, it is important to do cognitive testing on these children to determine any impairment," King said. "We hope that by preventing further lesions through blood transfusions that we can preserve their ability to think and learn."
A total of 71 percent of the school-aged children in the study were receiving special education services and 57 percent had failed a grade in school. Previous School of Medicine research shows that 80 percent of students with silent strokes perform poorly in school.
King said the results of the trial were encouraging to health-care professionals treating children with sickle cell disease.
"What we found in this trial is that families and children with sickle cell disease and who experience silent strokes are willing to commit to blood transfusion therapy for this condition," King said. "If these children are left untreated, their risk for an overt stroke is very high, but if we use blood transfusion therapy, they may have a lower risk for overt stroke and no evidence of new silent infarcts on an MRI."
Results of this Phase II trial spearheaded a larger, Phase III study that is evaluating 1,800 children in the United States, Canada and Europe. That trial, called the Silent Cerebral Infarct Multi-Center Clinical Trial, is headed by Michael R. DeBaun, M.D., professor of pediatrics at the School of Medicine. Through it, researchers will further determine the effectiveness of blood transfusion therapy to prevent silent strokes in children with sickle cell disease and to prevent further cerebral injury.
Washington University School of Medicine in St. Louis
Sickle Cell Disease Current Events and Sickle Cell Disease News RSSThinking outside the block in disease gene studies
In the decade since the Human Genome Project produced the first map of DNA sequences in the human genome, scientists throughout the world have combed through genome data to identify genes and gene variants that cause human disease.
Cholesterol-lowering drug shows promise against serious infections in sickle cell disease
New research suggests a family of widely used cholesterol-lowering drugs might help protect individuals from serious illness following bacterial infection, including the pneumococcal infections that pose a deadly threat to those with sickle cell disease.
Early lessons from the H1N1 pandemic: Critical illness in children unpredictable but survivable
Lessons learned from the first 13 children at Johns Hopkins Children's Center to become critically ill from the H1N1 virus show that although all patients survived, serious complications developed quickly, unpredictably, with great variations from patient to patient and with serious need for vigilant monitoring and quick treatment adjustments.
Blood Stem-Cell Transplant Regimen Reverses Sickle Cell Disease in Adults
A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.
'Mini' transplant may reverse severe sickle cell disease
Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.
New approach to sickle-cell disease shows promise in mice
A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston.
New study finds barriers to pain treatment in children with sickle cell disease
A new study by researchers from the Medical College of Wisconsin, in Milwaukee, found a substantial variation in hydroxyurea utilization for pain and other sickle cell disease complications in children.
Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome
For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder.
Drug shows promise in treating dangerous complication of erectile disorder
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston.
That '4 hour erection': new discovery may help prevent a complication of priapism
For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope.
More Sickle Cell Disease Current Events and Sickle Cell Disease News Articles
 |
Sickle Cell Disease (Genes and Disease) by Phill Jones (Author) In 1910, Dr. James B. Herrick published Western medical literature's first description of a person with sickle cell disease. Soon, other physicians reported patients with similar symptoms and confirmed the characteristic feature of the disease: elongated red blood cells. In 1922, the peculiar shape of the cells inspired the official name for the disorder. Within 30 years, scientists had learned about the cause of sickle cell disease - an abnormal form of hemoglobin. "Sickle Cell Disease" explores the scientific discoveries that led to an understanding of the genetic basis of the disease, explaining how a single mutation in hemoglobin multiplies into the many symptoms of sickle cell disease. Also investigated are treatments that help individuals manage sickle cell disease symptoms, and how... |
 |
To All My Friends on Shore Starring: Gloria Foster, Dennis Hines, Bill Cosby, Dennis Pate, Dennis Tate Directed By: Gilbert Cates Also With: Bill Cosby (Composer), Urs B. Furrer (Cinematographer), Angelo Ross (Editor) An touching heartwarming slice of life story about a hard working airport redcap (Bill Cosby) dreams of getting his son, Vandy (Dennis Hines) and his wife, Serera (Gloria Foster The Matrix) out of the ghetto and into a home of there own, only to discover |
 |
Understanding Sickle Cell Disease (Understanding Health and Sickness Series) by Ph.D., Miriam Bloom (Author) |
 |
Sickle Cell Disease: Pathophysiology, Diagnosis, and Management by Vipul N. Mankad (Editor), R. Blaine Moore (Editor) Sickle cell disease is a complex disease with a genetic mutation producing a wide variety of manifestations. It is of great public health importance nationally and internationally. While the conclusions of this study support the generally accepted views on the disease, the book provides the most recent information and state-of-the-art knowledge of the subject. The book is unique in that it presents the genetic, molecular, cellular, metabolic, rheologic, clinical, diagnostic, therapeutic, and psychosocial dimensions of sickle cell disease. Its synthesis of micro to macro, molecular to cellular, individual to social relationships provides a comprehensive study of sickle cell disease. |
 |
Sickle Cell Disease (Diseases and Disorders) by Lizabeth Peak (Author) |
|
Sickle Cell Disease (Oxford Medical Publications) by Graham R. Serjeant (Author) One of the most common inherited blood disorders, sickle cell disease affects large numbers of people throughout the world. This comprehensive volume provides an up-to-date review of the clinical management of sickle cell disease. Distilling the large amount of information scattered throughout the medical literature, Serjeant summarizes advances in three areas of clinical importance--diagnosis, clinical features, and therapy. He also offers a critical review of the extensive literature on the subject, and includes a comprehensive list of references. | |
 |
Uncertain Suffering: Racial Health Care Disparities and Sickle Cell Disease (George Gund Foundation Imprint in African American Studies) by Carolyn Rouse (Author) On average, black Americans are sicker and die earlier than white Americans. Uncertain Suffering provides a richly nuanced examination of what this fact means for health care in the United States through the lens of sickle cell anemia, a disease that primarily affects blacks. In a wide ranging analysis that moves from individual patient cases to the compassionate yet distanced professionalism of health care specialists to the level of national policy, Carolyn Moxley Rouse uncovers the cultural assumptions that shape the quality and delivery of care for sickle cell patients. She reveals a clinical world fraught with uncertainties over how to treat black patients given resource limitations and ambivalence. Her book is a compelling look at the ways in which the politics of racism, attitudes... |
 |
The Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease by Keith Wailoo (Author), Stephen Pemberton (Author) Why do racial and ethnic controversies become attached, as they often do, to discussions of modern genetics? How do theories about genetic difference become entangled with political debates about cultural and group differences in America? Such issues are a conspicuous part of the histories of three hereditary diseases: Tay-Sachs, commonly identified with Jewish Americans; cystic fibrosis, often labeled a "Caucasian" disease; and sickle cell disease, widely associated with African Americans. In this captivating account, historians Keith Wailoo and Stephen Pemberton reveal how these diseases -- fraught with ethnic and racial meanings for many Americans -- became objects of biological fascination and crucibles of social debate. Peering behind the headlines of breakthrough... |
 |
Sickle Cell Disease (Health Watch) by Susan Dudley Gold (Author), Lillian McMahon (Author) |
 |
Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease: A Biopsychosocial Approach by Ronald T. Brown (Editor) Over recent decades, tremendous advances in the prevention, medical treatment, and quality of life issues in children and adolescents surviving cancer have spawned a host of research on pediatric psychosocial oncology. This important volume fulfills the clear need for an up-to-date, comprehensive handbook for practitioners that delineates the most recent research in the field--the first of its kind in over a decade. Over 60 renowned authors have been assembled to provide a thorough presentation of the state-of-the art research and literature, with topics including: -Neuropsychological effects of chemotherapy and radiation therapy -Bone marrow transplantation -Important issues about quality of life during and following treatment -Collaborative research among child-focused... |
| © 2010 BrightSurf.com |